Evidence map›Paper›PMID 36687367›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis.

Shay Menascu, Michal Siegel-Kirshenbaum, Sapir Dreyer-Alster, Yehuda Warszawer, David Magalashvili, Mark Dolev, Mathilda Mandel, Gil Harari, Anat Achiron

Open access · goldAbstract read
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Controversies in neuroimmunology: Multiple sclerosis and other demyelinating disordersBiomedica : revista del Instituto Nacional de Salud · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shay MenascuMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Michal Siegel-KirshenbaumSackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Sapir Dreyer-AlsterMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Yehuda WarszawerMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.ORCID https://orcid.org/0000-0001-7919-807X
David MagalashviliMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Mark DolevMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Mathilda MandelMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Gil HarariMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Anat AchironMultiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.ORCID https://orcid.org/0000-0002-2020-3126
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Relapsing-remitting multiple sclerosis (RRMS) affects predominantly young women within reproductive years. As an increased risk of relapses is known to occur during the post-partum period, it is important to consider treatment options. Aim: Evaluate the effects of intravenous immunoglobulins (IVIg) to prevent post-partum relapses. Methods: We prospectively followed 198 pregnant female RRMS patients, 67 treated with IVIg during pregnancy and the three months post-partum, and 131 untreated patients that served as controls. Results: During the pre-gestation year, 41.4% were treated with immunomodulatory drugs, and 28.3% experienced a relapse. During pregnancy and the post-partum period, the number of relapsing patients significantly decreased in the IVIg group (37.3%, 10.4%, 8.9%, respectively, Conclusions: IVIg treatment proved efficient to reduce the rate and severity of relapses during pregnancy and the three-month post-partum.

Indexed as

Intravenous immunoglobulinsMultiple sclerosisPost-partumPregnancyRelapse

Identifiers

PMID36687367
PMCPMC9853871
OpenAlexW4317106026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.